Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000342 |
The purpose of this study is to evaluate clinical safety and pharmacological efficacy in the treatment of cocaine dependence, to evaluate impact of treatment on craving, and to correlate evidence of baseline neurotoxic damage of cocaine with treatment outcome and clinical side-effects.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders |
Drug: Risperidone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | Risperidone for the Treatment of Cocaine Dependence |
Ages Eligible for Study: | 21 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
United States, California | |
Friends Research Institute | |
Los Angeles, California, United States, 90025 |
Principal Investigator: | Walter Ling, M.D. | Friends Research Institute, Inc. |
Study ID Numbers: | NIDA-3-0010-7, Y01-3-0010-7 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000342 |
Health Authority: | United States: Federal Government |
Cocaine-Related Disorders Dopamine Mental Disorders Risperidone |
Substance-Related Disorders Disorders of Environmental Origin Cocaine Serotonin |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |